Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2018
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Acute Myeloid Leukemia Treatment Episodes Linked to Significant Economic Burden
By
Chase Doyle
Economics & Value
,
Value-Based Care
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—A retrospective analysis of a large commercial payer database has demonstrated a link between various treatment episodes of acute myeloid leukemia and substantial economic burden. According to data presented at ASH 2017, healthcare resource use and direct healthcare costs were associated with high-intensity chemotherapy induction, hematopoietic stem-cell transplantation (HSCT), and episodes of relapsed or refractory disease in a US commercially insured population.
Read Article
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Economics & Value
,
Multiple Myeloma
,
Value-Based Care
,
Hematologic Malignancies
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—A recent analysis of a commercial claims database suggests that oral therapy for multiple myeloma may help decrease the economic burden for patients and healthcare systems. According to data presented at ASH 2017, patients with multiple myeloma who received injectable therapy used significantly more disability benefits and incurred higher productivity costs than patients who received oral medications.
Read Article
Which Combination Immunotherapies to Use, and When? High Response Rates, but Serious Toxicity Remains a Concern
By
Chase Doyle
Immunotherapy
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—As single-agent immunotherapies continue to show promising results, the challenge is now to determine which combination regimens with immunotherapies can improve outcomes. According to data presented at ASH 2017, 3 approaches are currently being explored.
Read Article
Novel TKI Leads to Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
By
Wayne Kuznar
Immunotherapy
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—A novel, third-generation, oral tyrosine kinase inhibitor (TKI), PF-114 mesylate, has antileukemic activity in heavily pretreated patients with chronic myeloid leukemia (CML), including those with
T315I
mutation, said Jorge E. Cortes, MD, Deputy Chair, Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, at ASH 2017.
Read Article
CAR T-Cell Therapy Shows “Impressive” Results in Multiple Myeloma
By
Wayne Kuznar
Hematologic Malignancies
,
Immunotherapy
,
Multiple Myeloma
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—Although chimeric antigen receptor (CAR) T-cell therapies directed against the CD19 protein garnered much attention at ASH 2017, CAR T-cells targeting B-cell maturation antigen (BCMA), a protein expressed nearly universally on multiple myeloma cells, were found to be remarkably effective in patients with heavily pretreated multiple myeloma.
Read Article
Quizartinib Combinations Show High Activity in Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—The combination of the investigational drug quizartinib plus azacitidine (Vidaza) or low-dose cytarabine has substantial activity in patients with myeloid leukemias and
FLT3
mutations.
Read Article
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—Treatment with ivosidenib, an IDH1 inhibitor, resulted in an objective response rate (ORR) of 41.6% in a phase 1 dose-escalation and expansion clinical trial in patients with relapsed or refractory acute myeloid leukemia (AML) and
IDH1
mutation.
Read Article
First-in-Class Sotatercept Improves Hemoglobin Levels in Anemic Patients with Myelofibrosis
By
Wayne Kuznar
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—Sotatercept, an investigational activin receptor IIA ligand trap, when used alone or in combination with ruxolitinib (Jakafi), safely increases hemoglobin levels in patients with myeloproliferative neoplasm–associated myelofibrosis, according to data from a phase 2, investigator-initiated clinical trial, presented at ASH 2017.
Read Article
Mogamulizumab, Anti-CCR4 Antibody, Improves Survival in Patients with Advanced Cutaneous T-Cell Lymphoma
By
Charles Bankhead
Emerging Therapies
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—Mogamulizumab, a monoclonal antibody targeting CC chemokine receptor type 4 (CCR4), significantly reduced the risk for disease progression or death in patients with untreated cutaneous T-cell lymphoma (CTCL) compared with vorinostat (Zolinza), reported Youn H. Kim, MD, Director, Multidisciplinary Cutaneous Lymphoma Program, Stanford Medicine, California, at ASH 2017.
Read Article
CAR T-Cell Therapy Makes Significant Inroads in Lymphoma: Kymriah and Yescarta Show Durable Remissions
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—CD19-directed chimeric antigen receptor (CAR) T-cell therapy continues to show excellent and durable responses in patients with lymphoma who have no other treatment options. Two studies presented at ASH 2017 provide encouraging news for 2 new drugs, including long-term follow-up of the pivotal ZUMA-1 study of the CAR T-cell therapy axicabtagene ciloleucel (Yescarta), and primary results from the JULIET study of tisagenlecleucel (Kymriah).
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma